ViroPharma (VPHM) Posts Q3 EPS of $0.26, In-Line with Estimates
More News related to VPHM
- ViroPharma (VPHM) Updates on Cinryze FY09 Sales
- ViroPharma (VPHM) Acquires Rights for Cinryze Development and Commercialization
- ViroPharma Provides 2010 Cinryze(TM) (C1 Esterase Inhibitor [Human]) Outlook
- ViroPharma Expands Global Licensing, Commercialization and Development Rights for Cinryze(TM) (C1 esterase inhibitor [human])
- ViroPharma to Participate in the 28th Annual J.P. Morgan Healthcare Conference
More News related to Earnings
- HNI Corporation (HNI) Tops Q1 EPS by 2c; Revs Light
- Team Health (TMH) Reports Mixed Q4 Results
- Baidu (BIDU) Blows the Lid Off Q4, Shares Jump
- Aspen Insurance (AHL) Posts Q4 adj.-EPS of $1.44, Tops Views
- Acadia Realty Trust (AKR) Misses Q4 FFO by 1c; Guides Below for FY10
ViroPharma (NASDAQ: VPHM) reports Q3 EPS of $0.26, in-line the analyst estimate of $0.26. Revenue for the quarter was $81 million, which compares to the estimate of $84.22 million.
Related Categories
EarningsStocks Mentioned
+0.35Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
